Poor phenotype-genotype association in a large series of patients with type III Bartter syndrome.

Alejandro García Castaño[1], Gustavo Pérez de Nanclares[1], Leire Madariaga[2, 3], Mireia Aguirre[2], Álvaro Madrid[4], Sara Chocrón[4], Inmaculada Nadal[5], Mercedes Navarro[6], Elena Lucas[7], Julia Fijo[8], Mar Espino[9], Zilac Espitaletta[10], Víctor García Nieto[11], David Barajas de Frutos[12], Reyner Loza[13], Guillem Pintos[14] Luis Castaño[1, 3, 15], RenalTube Group[1, 4, 11, 16], Gema Ariceta[4].

1 BioCruces Institute, Ciberer, Cruces University Hospital, Bizkaia, Spain; 2 Pediatric Nephrology, Cruces University Hospital, Bizkaia, Spain; 3 Department of Pediatrics, School of Medicine and Odontology, University of Basque Country UPV/EHU, Bizkaia, Spain; 4 Pediatric Nephrology, Vall d'Hebron University Hospital, Universitat Autonoma, Barcelona, Spain; 5 Pediatric Nephrology, Virgen del Camino Hospital, Pamplona, Spain; 6 Pediatric Nephrology, La Paz University Hospital, Madrid, Spain; 7 Pediatrics, Manises Hospital, Valencia, Spain; 8 Pediatric Nephrology, Virgen del Rocío Hospital, Sevilla, Spain; 9 Pediatric Nephrology, Fundación Alcorcón University Hospital, Madrid, Spain; 10 San Ignacio University Hospital, Bogotá, Colombia; 11 Pediatric Nephrology, Nuestra Señora de Candelaria University Hospital, Tenerife, Canarias, Spain; 12 Pediatric Nephrology, Virgen de las Nieves Hospital, Granada, Spain; 13 Nephrology Unit, Cayetano Heredia University, Cayetano Heredia Hospital, Lima, Peru; 14 Germans Trias i Pujol University Hospital, Badalona, Spain; 15 Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; 16 Pediatric Nephrology, Asturias Central University Hospital, Oviedo, Asturias, Spain.

Corresponding author: gariceta@vhebron.net

S1 Table. Comparison of clinical and biochemical characteristics of different cohorts of patients with confirmed type III BS.

	This study (n=30)		Simon *et al.* (n=17) [2]		Konrad *et al.* (n=36) [10]		Peters *et al.* (n=20) [14]		Bettinelli *et al.* (n=13) [11]		Lee *et al.* (n=23) [13]	
	n	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**
Polyhydramnios	9/24	37	NA	NA	8/25	32	5/20	25	2/13	15	NA	±22
Diagnosis ≤ 1 year	16/30	53	12/17	70	22/34	65	11/20	55	10/13	77	20/23	87
Hypokalemia*	30/30	100	17/17	100	36/36	100	13/20	65	13/13	100	23/23	100
Hyponatremia*	17/29	59	NA	NA	NA	NA	NA	NA	7/13	54	NA	NA
Hypochloremia*	21/28	75	NA	NA	NA	NA	5/20	25	13/13	100	23/23	100
Metabolic alkalosis*	27/29	93	17/17	100	NA	100	4/20	20	13/13	100	23/23	100
Magnesemia*	6/26 (Low)	23	17/17 (Normal)	100	9/23 (Low)	39	NA (Low)	±50	3/13 (Low)	23	5/23 (Low)	22
Hyperreninemia*	20/20	100	6/6	100	NA	100	NA	NA	13/13	100	23/23	100
Hyperaldosteronism*	19/22	86	6/6	100	NA	100	NA	NA	13/13	100	23/23	100
Calciuria*	6/26 (Low) 8/26 (High)	23 31	11/17 (High)	65	2/25 (Low) / 7/25 (High)	8/ 28	10/20 (High)	50	2/13 (Low) / 1/13 (High)	15/ 8	13/23 (High)	56
Nephrocalcinosis	6/30	20	0/17	0	4/25	16	2/20	10	0/13	0	4/23	17

Abbreviations: n, number of patients; NA, not available. *According to our laboratory reference values.